The clinical applications of cell therapies span diverse disease areas, from hematologic malignancies and solid tumors to autoimmune disorders and rare genetic diseases. The Cell Therapy Market is benefiting from this diverse demand, with the oncology segment currently dominating the market.

Hematologic Malignancies

CAR-T Therapy for B-Cell Malignancies

CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, with approved products including Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma. Yescarta has over 570 authorized treatment centers worldwide, including more than 160 in the U.S. . CAR-T therapy has become a standard treatment for relapsed/refractory B-cell malignancies.

Multiple Myeloma

CAR-T therapies targeting BCMA, such as Abecma and Carvykti, have shown significant efficacy in multiple myeloma. The Abecma segment is projected to grow at a rate of 13.76% . Ongoing research is expanding the use of CAR-T in earlier lines of therapy.

Non-Hodgkin Lymphoma

CAR-T therapies have demonstrated high response rates in relapsed/refractory large B-cell lymphoma and follicular lymphoma. Grade ≥3 neurotoxicity occurred in approximately 32% of patients with large B-cell lymphoma receiving Yescarta, highlighting the importance of specialized care .

Solid Tumor Applications

Melanoma

In February 2024, the U.S. FDA approved AMTAGVI (lifileucel), a T cell immunotherapy indicated for advanced melanoma . This approval marks a significant milestone in expanding cell therapy beyond hematologic malignancies.

Renal Cell Carcinoma

Allogene Therapeutics announced Phase 1 data for ALLO-316 in June 2025, an AlloCAR T investigational product targeting CD70, showing potential in providing clinical benefit in advanced or metastatic renal cell carcinoma .

Emerging Solid Tumor Targets

Due to the huge untapped market in solid tumors, companies are now designing CAR T cells to recognize multiple antigens simultaneously (dual or tri-CARs) to overcome antigen escape. With growing efforts, regulatory bodies are supportive toward approving innovative products for solid tumors .

Rare Diseases and Genetic Disorders

Sickle Cell Disease

According to the World Health Organization, around 7.74 million individuals were living with sickle cell disease in 2021 across the globe. Such a large patient population increases the demand for targeted therapies and is expected to propel market growth .

Genetic Disorders

Cell therapies can address rare genetic diseases, many of which are fatal in infancy. Currently, around 95% of rare diseases do not have FDA-approved treatment. The potential for curative, one-time treatments makes cell therapy a high-priority field for rare diseases .

Regenerative Medicine Applications

Stem cell therapies are being investigated for autoimmune disorders, neurological conditions, and cardiovascular diseases. Continuous research on stem cells and new applications are anticipated to create new avenues over the forecast period .

Autoimmune Disorders

Emerging Applications

Cell therapies are being explored for autoimmune disorders including multiple sclerosis and rheumatoid arthritis. These applications demand chronic treatment models and long-term safety surveillance . The expansion of cell therapies into autoimmune indications represents a significant growth opportunity.

CAR-T in Autoimmunity

The potential for CAR-T therapies to reset the immune system in autoimmune disorders is being investigated. Allogeneic "off-the-shelf" approaches may offer advantages in autoimmune applications where patient-specific therapies may not be feasible .

Clinical Development

Autoimmune applications require distinct strategic approaches, with chronic treatment models and long-term safety surveillance. The industry is increasingly focused on improving manufacturing scalability and reducing production timelines to support expansion into new indications .

End-User Applications

Hospitals

Hospitals are the primary setting where cell therapies are administered, due to the presence of specialized infrastructure, availability of multidisciplinary care, and alignment with reimbursement frameworks. Kauvery Hospital in Chennai, India, launched CAR-T therapy for cancer treatment in May 2025 .

Specialty Clinics

Specialty clinics are emerging as a fast-growing segment, projected to grow at a CAGR of 35.26% . These clinics offer focused expertise in cell therapy administration and patient management.

Research Institutions

Academic and research institutes play a critical role in cell therapy development, with investigator-initiated trials and translational research driving innovation. The fastest-growing end-user segment includes research institutes and academic institutions .

Future Clinical Directions

Earlier Lines of Therapy

Cell therapies are being evaluated in earlier lines of therapy, potentially improving outcomes and expanding the addressable patient population. Clinical trials are investigating CAR-T in frontline settings .

Combination Approaches

Combination of cell therapies with other modalities, including checkpoint inhibitors and targeted therapies, may enhance efficacy and overcome resistance. Combination approaches are a key area of clinical research .

Personalized Medicine Integration

The personalized nature of cell therapies aligns well with the precision medicine required to treat the unique genetic underpinnings of many diseases. Personalized cell therapies are at the forefront of precision medicine .

The Cell Therapy Market continues expanding across clinical applications, from hematologic malignancies to solid tumors. Cell therapies are essential for modern oncology and regenerative medicine, supporting improved outcomes across diverse patient populations.